Based in Mississauga, Canada, Profound Medical Corp. continues to solidify its position within the global health care sector as a specialized developer and commercializer of advanced medical technologies. The company focuses its research and commercial efforts on the development of innovative solutions for localized prostate cancer treatments, aiming to provide precision-based alternatives for patients worldwide.
Operating within the health care equipment and supplies industry, Profound Medical Corp. maintains a significant presence on the Toronto Stock Exchange. As of the market close on November 16, 2026, the company’s shares were valued at 10.05 CAD. This valuation reflects a period of notable movement over the past year; the stock reached a 52-week high of 12.4 CAD in January 2026, following a 52-week low of 6.52 CAD recorded in March 2026.
With a market capitalization of 383,483,072 CAD, the company represents a specialized player in the medical device landscape. While the company currently reports a price-to-earnings ratio of -7.65, its strategic focus remains centered on the global expansion of its proprietary technologies designed to transform the standard of care for prostate cancer patients.




